<DOC>
	<DOCNO>NCT02015299</DOCNO>
	<brief_summary>Diabetes associate increase risk develop premature macrovascular complication . The process irreversible subclinical damage vasculature already start precede stage . Dipeptidyl peptidase ( DPP ) -4 inhibitor show attenuate vascular damage preclinical study . Off-target effect adipose tissue inflammation , liver steatosis atherosclerotic plaque extensively document animal study . Based consideration investigator hypothesize early therapy DPP4 inhibitor linagliptin subject treatment naive type 2 diabetes lead beneficial effect arterial stiffness measure pulse wave velocity .</brief_summary>
	<brief_title>Off taRget Effects Linagliptin monothErapy Arterial Stiffness Early Diabetes</brief_title>
	<detailed_description>Patients type 2 diabetes mellitus ( T2DM ) increase risk develop premature macrovascular complication . The process irreversible subclinical damage vasculature already start precede stage . At diagnosis , patient T2DM already evidence subclinical vascular damage . Recent trial show benefit glucose lower therapy start later course disease , implicate early intervention could effective prevent macrovascular complication . Dipeptidyl peptidase ( DPP ) -4 inhibitor oral antidiabetic drug increase action naturally gut hormone glucagon-like peptide-1 ( GLP-1 ) , lead improvement postprandial insulin secretion , without hypoglycaemia weight gain . DPP4 inhibitor improve beta-cell function insulin resistance . More importantly , off-target effect adipose tissue inflammation , liver steatosis atherosclerotic plaque extensively document animal study . Furthermore , DDP4 inhibitor improve cardiovascular risk profile small clinical study . Based consideration investigator hypothesize early therapy DPP4 inhibitor linagliptin subject type 2 diabetes lead beneficial effect arterial stiffness , blood pressure inflammatory marker independent effect glycemic control .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Men woman , age 30 70 year , AND Treatment naïve type 2 diabetes , define Fasting plasma glucose ≥ 7.0 mmol/l , OR Random plasma glucose ≥ 11.1 mmol/l , OR HbA1c ≥6,5 % Written inform consent Assessable Pulse Wave Velocity measurement screen Current previous use glycemic control medication Type 1 diabetes Gestational diabetes mellitus Other specific type diabetes due cause , e.g. , genetic defect βcell function , genetic defect insulin action , diseases exocrine pancreas ( cystic fibrosis ) , drug chemicalinduced ( treatment HIV/AIDS organ transplantation ) Uncontrolled hypertension , define systolic blood pressure &gt; 160 diastolic blood pressure &gt; 100 mmHg screen visit Severe dyslipidemia indicate primary dyslipidemia , define total cholesterol &gt; 8 mmol/l , triglycerides &gt; 10 mmol/l high density lipoprotein cholesterol &lt; 0.6 mmol/l Current use weight loss medication previous weight loss surgery History severe gastrointestinal disease Clinical contraindication DPP4inhibitors Previous cardiovascular disease , define stable coronary artery disease acute coronary syndrome , stroke transient ischemic attack , peripheral artery disease Symptomatic heart failure , New York Heart Association ( NYHA ) class IIIV Women currently pregnant , plan become pregnant , breastfeed woman , woman child bear potential use appropriate contraceptive measure Clinically significant liver disease hepatic function great 3 time upper limit normal Known impair renal function eGFR &lt; 30 ml/min/1.73m2 Patients mentally incompetent sign Patient Informed Consent Current active malignancy previous 6 month Documented HIV infection Use rifampicin</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Pulse Wave Velocity</keyword>
	<keyword>Dipeptidyl peptidase ( DPP ) -4 inhibitor</keyword>
	<keyword>Linagliptin</keyword>
	<keyword>Arterial Stiffness</keyword>
	<keyword>Subclinical arterial inflammation</keyword>
</DOC>